StrokeCANTONCT06928675
Cell-free DNA in Acute Stroke
An observational study of Stroke, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
Trial summary
Cell-free DNA (cfDNA) is an important pro-inflammatory and prothrombotic mediator. With this study the investigators aim to gain new insights into the role of cfDNA in stroke and to perform a combined analysis of cfDNA in the hyperacute phase of the disease using blood and thrombus analyses. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Stroke
- How many people
- 200 participants
- Where
- 1 siteSwitzerland
- Study dates
- 30 Mar 2025to 1 Sep 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: male or female patients over 18 years of age presenting with acute ischemic stroke due to large vessel occlusion (LVO) who require mechanical thrombectomy.
Who may be able to join
- Acute ischemic stroke due to large vessel occlusion (LVO) who require mechanical thrombectomy (detected in CT-Scan or MRI-Scan)
- 18 years of age
Who cannot join
- Patients currently undergoing immunological therapies.
- Patients with immunological diseases
- Patients with systemic infections at the time of admission
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Switzerland1 site, 1 recruiting
- Recruiting
University Hospital Basel
Basel, 4031
Gerrit Grosse, PD Dr. Dr., +41 61 32 85265, gerrit.grosse@usb.ch
Gerrit Grosse, PD Dr. Dr.
About this study
Official title: CANTO - Cell-free DNA in Acute Stroke
Cell-free DNA (cfDNA) is an important pro-inflammatory and prothrombotic mediator. With this study the investigators aim to gain new insights into the role of cfDNA in stroke and to perform a combined analysis of cfDNA in the hyperacute phase of the disease using blood and thrombus analyses. The main objectives are to analyse cfDNA in different stroke etiologies, to investigate the relationship between cfDNA and important procedural factors such as secondary embolisation and reperfusion outcomes, to analyse the correlation between blood and thrombus content of cfDNA and to investigate the specific source of cfDNA in distinct stroke subtypes.
- Conditions
- Stroke
- Keywords
- cell-free DNA, stroke etiologies, reperfusion, secondary emboli, stroke subtypes
- Medical subject headings
- Stroke
What is being measured
The primary outcome is the main question the study is designed to answer.
Stroke Etiology
Descriptive comparison of cell-free DNA in cerebral thrombi regarding stroke etiology
Measured: at day 1
Secondary outcomes (5)
Correlation cfDNA concentration and perfusion outcome
cfDNA abount in blood and thromi is assessed in relation to thrombectomy outcomes including perfusion outcome
Measured: at day 1
Correlation cfDNA concentration and secondary embolism
cfDNA abount in blood and thromi is assessed in relation to thrombectomy outcomes including secondary embolism
Measured: at day 1
Correlation cfDNA concentration and thrombus fragmentation.
cfDNA abount in blood and thromi is assessed in relation to thrombectomy outcomes including thrombus fragmentation
Measured: at day 1
Measures of cfDNA as a marker of systemic inflammation
to correlate cfDNA amount in blood and thrombi
Measured: at day 1
90-day functional outcomes
to examine the association between cfDNA concentrations in blood and thrombi with 90-day functional outcomes.
To assess functional outcomes, the modified Rankin Scale (mRS) is evaluated via a structured telephone interview on day 90. A favorable outcome is defined as an mRS score of 0 to 2 points, while an unfavorable outcome is defined as an mRS score of 3 to 5 points.
Measured: up to 3 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Apr 2025
- Study start30 Mar 2025
- Primary completion1 Sep 2026 (estimated)
- Study completion1 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for StrokeStudies of the same condition, open and under way.
- More trials run by University Hospital, Basel, SwitzerlandThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Basel, Switzerland
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Gerrit Grosse, PD Dr. Dr., Principal investigator, University Hospital, Basel, Switzerland
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06928675
- Sponsor's protocol ID
- 2025-00235; ko24grosse2
- Other IDs
- 2025
- Acronym
- CANTO
- Status last verified
- Apr 2025
- First submitted
- 18 Mar 2025
- Last updated
- 15 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- CANTO - Cell-free DNA in Acute Stroke
- ClinicalTrials.gov ID
- NCT06928675
- Acronym / sponsor ID
- CANTO / 2025-00235; ko24grosse2
- Conditions
- Stroke
- Keywords
- cell-free DNA, stroke etiologies, reperfusion, secondary emboli, stroke subtypes
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- University Hospital, Basel, SwitzerlandUniversity, hospital or other
- Study start
- 30 Mar 2025 (actual)
- Primary completion
- 1 Sep 2026 (estimated)
- Study completion
- 1 Sep 2026 (estimated)
- First posted
- 15 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cell-free DNA (cfDNA) is an important pro-inflammatory and prothrombotic mediator. With this study the investigators aim to gain new insights into the role of cfDNA in stroke and to perform a combined analysis of cfDNA in the hyperacute phase of the disease using blood and thrombus analyses. The main objectives are to analyse cfDNA in different stroke etiologies, to investigate the relationship between cfDNA and important procedural factors such as secondary embolisation and reperfusion outcomes, to analyse the correlation between blood and thrombus content of cfDNA and to investigate the specific source of cfDNA in distinct stroke subtypes.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- male or female patients over 18 years of age presenting with acute ischemic stroke due to large vessel occlusion (LVO) who require mechanical thrombectomy.
Key inclusion criteria (2 listed)
- Acute ischemic stroke due to large vessel occlusion (LVO) who require mechanical thrombectomy (detected in CT-Scan or MRI-Scan)
- 18 years of age
Key exclusion criteria (3 listed)
- Patients currently undergoing immunological therapies.
- Patients with immunological diseases
- Patients with systemic infections at the time of admission
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Stroke Etiology
Time frame: at day 1
Descriptive comparison of cell-free DNA in cerebral thrombi regarding stroke etiology
5 secondary outcomes
Correlation cfDNA concentration and perfusion outcome
Time frame: at day 1
Correlation cfDNA concentration and secondary embolism
Time frame: at day 1
Correlation cfDNA concentration and thrombus fragmentation.
Time frame: at day 1
Measures of cfDNA as a marker of systemic inflammation
Time frame: at day 1
90-day functional outcomes
Time frame: up to 3 month
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Apr 2025.
Related trials for Stroke
Not yet recruiting
Foot Drop Rehabilitation and Mobility in Chronic Stroke
Stroke
Enrolling by invitation
Study on the Efficacy and Safety of Non-Invasive Brain-Computer Interface With MRI-Guided Multi-Channel Time-Domain Interference Stimulation in Treating Motor Dysfunction in Acute Cerebral Infarction Patients
Acute Ichemic Stroke
RecruitingObservational study
Development, Validation and Normative Data of the Italian Battery for the Recognition of Famous Faces (FAME)
Stroke, Alzheimer s Disease
Enrolling by invitation
Long-Term Clinical, Health Economic, and Process Evaluation of Intensive Technology-Integrated Motor Rehabilitation in Chronic Neurological Conditions (INTeRAcT-bis)
Stroke, Spinal Cord Injuries (SCI)
Not yet recruitingPhase 2
Rimonabant for Improving Walking Ability in Patients With Chronic Stroke
Chronic Stroke
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Gerrit Grosse, PD Dr. Dr. principal investigator
University Hospital, Basel, Switzerland
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Stroke, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Gerrit Grosse, PD Dr. Dr. (+41 61 32 85265, gerrit.grosse@usb.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Stroke Etiology (time frame: at day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Apr 2025.